UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

KRAS: Reasons for optimism in lung cancer

Lindsay, CR; Jamal-Hanjani, M; Forster, M; Blackhall, F; (2018) KRAS: Reasons for optimism in lung cancer. European Journal of Cancer , 99 pp. 20-27. 10.1016/j.ejca.2018.05.001. Green open access

[thumbnail of lindsayetal.pdf]
Preview
Text
lindsayetal.pdf - Accepted Version

Download (896kB) | Preview

Abstract

Despite being the most frequent gain-of-function genetic alteration in human cancer, KRAS mutation has to date offered only limited potential as a prognostic and predictive biomarker. Results from the phase III SELECT-1 trial in non-small cell lung cancer (NSCLC) recently added to a number of historical and more contemporary disappointments in targeting KRAS mutant disease, including farnesyl transferase inhibition and synthetic lethality partners such as STK33. This narrative review uses the context of these previous failures to demonstrate how the knowledge gained from these experiences can be used as a platform for exciting advances in NSCLC on the horizon. It now seems clear that mutational subtype (most commonly G12C) of individual mutations is of greater relevance than the categorical evaluation of KRAS mutation presence or otherwise. A number of direct small molecules targeted to these subtypes are in development and have shown promising biological activity, with some in the late stages of preclinical validation.

Type: Article
Title: KRAS: Reasons for optimism in lung cancer
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ejca.2018.05.001
Publisher version: http://dx.doi.org/10.1016/j.ejca.2018.05.001
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Science & Technology, Life Sciences & Biomedicine, Oncology, KRAS, NSCLC, RAS, Non-small cell lung cancer, G12C, INHIBITOR TRAMETINIB GSK1120212, SYNTHETIC LETHAL INTERACTION, SELUMETINIB PLUS DOCETAXEL, ONCOGENIC K-RAS, NUCLEOTIDE EXCHANGE, PHASE-II, ANTITUMOR-ACTIVITY, PANCREATIC-CANCER, SMALL MOLECULES, MUTATION STATUS
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: https://discovery.ucl.ac.uk/id/eprint/10055450
Downloads since deposit
621Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item